ANNUAL REPORT 2020
In this Issue
For image credits, view PDF
When Joyce Liao, MD, PhD, associate professor of ophthalmology and of neurology, came to Stanford in 2006, she began seeing patients with optic disc drusen (ODD), a condition that effects vision and the optic nerve, and was frustrated with how little she could offer them.
In clinical trials, both patients and faculty have to carefully balance potential benefits against potential risks in deciding who should be in a clinical trial—and this year the Byers Eye Institute at Stanford faced a new risk in that calculation.
For some, hearing the words artificial intelligence, or AI, sparks imaginative scenes of robot overlords, self-driving cars, dystopian surveillance, chatbots, and machines replacing humans at work.
Corneal blindness is a leading cause of blindness worldwide. More than 12 million patients remain on cornea transplant waitlists while suffering from corneal blindness, but an idea from one researcher may have an answer.